At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 635 enrolled
Drug / intervention
liraglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating liraglutide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 635 participants across 47 sites.
Detailed Summary
This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedJul 2015
Primary CompletionMay 2017
Study CompletionNov 2017
TodayJul 2026
First PostedJul 22, 2015
Enrollment StartJul 21, 2015
Primary CompletionMay 2, 2017
Study CompletionNov 9, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.9 years ago
Interventions
liraglutidedrug
Injected subcutaneously s.c. (under the skin) once daily.